Setmelanotide

Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

Open-Label Extension Study of Setmelanotide

Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

A Study of Setmelanotide in Patients With Prader-Willi Syndrome

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

Long Term Extension Trial of Setmelanotide

Open-Label Study of Setmelanotide in Hypothalamic Obesity

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity

Setmelanotide in a Single Patient With Partial Lipodystrophy